<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643693</url>
  </required_header>
  <id_info>
    <org_study_id>P3L-PK-02-US</org_study_id>
    <secondary_id>P3L-PK-02-US</secondary_id>
    <nct_id>NCT02643693</nct_id>
  </id_info>
  <brief_title>User Acceptability of P3L</brief_title>
  <official_title>User Acceptability of a Nicotine Lactate Delivery System Relative to the VUSE e-Cigarette System and Combustible Cigarette Comparators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide an initial assessment of the acceptability of the Nicotine Lactate
      Delivery System (P3L) after ad libitum use and the ability of combustible cigarette (CC)
      smokers to use P3L to maintain their customary nicotine intake.

      The pharmacokinetics (PK) and pharmacodynamics (PD, i.e., subjective effects) profiles, will
      be evaluated as well as the safety and tolerability of the P3L.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study for an individual subject will be between 3 and 8 weeks,
      including 1 day for the screening visit, 3 days for the ad libitum use sessions (P3L, VUSE
      e-cigarette system and subjects' own commercially available non-menthol CC), 1 day for the
      preference evaluation session (subjects will be given the choice of using ad libitum the P3L
      or the VUSE), the 2 to 10 days of interval between each visit, and 7 days for the passive
      safety follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the plasma concentration of nicotine and cotinine during the 1st ad libitum use session for the P3L, the VUSE and subjects' own brand of non-menthol CC</measure>
    <time_frame>During the 3-hour ad libitum product use session</time_frame>
    <description>Visit 2: 2 blood samples collected prior to product use to provide baseline measures and 2 blood samples after the ad libitum product use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the plasma concentration of nicotine and cotinine during the 2nd ad libitum use session for the P3L, the VUSE and subjects' own brand of non-menthol CC</measure>
    <time_frame>During the 3-hour ad libitum product use session</time_frame>
    <description>Visit 3: 2 blood samples collected prior to product use to provide baseline measures and 2 blood samples after the ad libitum product use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the plasma concentration of nicotine and cotinine during the 3rd ad libitum use session for the P3L, the VUSE and subjects' own brand of non-menthol CC</measure>
    <time_frame>During the 3-hour ad libitum product use session</time_frame>
    <description>Visit 4: 2 blood samples collected prior to product use to provide baseline measures and 2 blood samples after the ad libitum product use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of nicotine withdrawal symptoms using the total score of the short version of the Questionnaire of Smoking Urges (QSU-brief) during the 1st ad libitum product use session</measure>
    <time_frame>During the 3-hour ad libitum product use session</time_frame>
    <description>Visit 2: assessed during the ad libitum use sessions for the P3L, the VUSE or the subjects' own brand of non-menthol CC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of nicotine withdrawal symptoms using the total score of the short version of the Questionnaire of Smoking Urges (QSU-brief) during the 2nd ad libitum product use session</measure>
    <time_frame>During the 3-hour ad libitum product use session</time_frame>
    <description>Visit 3: assessed during the ad libitum use sessions for the P3L, the VUSE or the subjects' own brand of non-menthol CC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of nicotine withdrawal symptoms using the total score of the short version of the Questionnaire of Smoking Urges (QSU-brief) during the 3rd ad libitum product use session</measure>
    <time_frame>During the 3-hour ad libitum product use session</time_frame>
    <description>Visit 4: assessed during the ad libitum use sessions for the P3L, the VUSE or the subjects' own brand of non-menthol CC.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Sequence 1 (P3L-VUSE-CC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will use ad libitum P3L on Visit 2, VUSE on Visit 3 and CC on Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 (P3L - CC - VUSE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will use ad libitum P3L on Visit 2, CC on Visit 3 and VUSE on Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3 ( VUSE - CC - P3L)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will use ad libitum VUSE on Visit 2, CC on Visit 3 and P3L on Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4 (VUSE - P3L - CC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will use ad libitum VUSE on Visit 2, P3L on Visit 3 and CC on Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5 (CC - P3L - VUSE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will use ad libitum CC on Visit 2, P3L on Visit 3 and VUSE on Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6 (CC - VUSE - P3L)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will use ad libitum CC on Visit 2, VUSE on Visit 3 and P3L on Visit 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3L</intervention_name>
    <description>Ad libitum use for a maximum of three hours.
P3L delivers on average 80 µg of nicotine per puff under Health Canada Intense smoking regime.</description>
    <arm_group_label>Sequence 1 (P3L-VUSE-CC)</arm_group_label>
    <arm_group_label>Sequence 2 (P3L - CC - VUSE)</arm_group_label>
    <arm_group_label>Sequence 3 ( VUSE - CC - P3L)</arm_group_label>
    <arm_group_label>Sequence 4 (VUSE - P3L - CC)</arm_group_label>
    <arm_group_label>Sequence 5 (CC - P3L - VUSE)</arm_group_label>
    <arm_group_label>Sequence 6 (CC - VUSE - P3L)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VUSE</intervention_name>
    <description>Ad libitum use for a maximum of three hours.
VUSE delivers on average 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime.</description>
    <arm_group_label>Sequence 1 (P3L-VUSE-CC)</arm_group_label>
    <arm_group_label>Sequence 2 (P3L - CC - VUSE)</arm_group_label>
    <arm_group_label>Sequence 3 ( VUSE - CC - P3L)</arm_group_label>
    <arm_group_label>Sequence 4 (VUSE - P3L - CC)</arm_group_label>
    <arm_group_label>Sequence 5 (CC - P3L - VUSE)</arm_group_label>
    <arm_group_label>Sequence 6 (CC - VUSE - P3L)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CC</intervention_name>
    <description>Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.</description>
    <arm_group_label>Sequence 1 (P3L-VUSE-CC)</arm_group_label>
    <arm_group_label>Sequence 2 (P3L - CC - VUSE)</arm_group_label>
    <arm_group_label>Sequence 3 ( VUSE - CC - P3L)</arm_group_label>
    <arm_group_label>Sequence 4 (VUSE - P3L - CC)</arm_group_label>
    <arm_group_label>Sequence 5 (CC - P3L - VUSE)</arm_group_label>
    <arm_group_label>Sequence 6 (CC - VUSE - P3L)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoking, healthy subject as judged by the Investigator

          -  Subject smoked at least 10 commercially available non-menthol CCs per day for the last
             12 months

          -  Subject does not plan to quit smoking in the next 60 days

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason)

          -  Subject has donated or been in receipt of whole blood or blood products within 3
             months prior to the screening visit

          -  Subject has used tobacco products or nicotine containing products other than CCs
             within 30 days prior to the screening visit

          -  Female subject is pregnant or breast feeding

          -  Female subject does not agree to use an acceptable method of effective contraception

          -  Female subject uses estrogen-containing hormonal contraception or hormone replacement
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jed E. Rose, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rose Research Center, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rose Research Center, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conventional cigarette</keyword>
  <keyword>Nicotine lactate delivery system</keyword>
  <keyword>e-cigarette</keyword>
  <keyword>VUSE</keyword>
  <keyword>Combustible cigarette</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 9, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

